Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pseudotropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.41 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.41 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.41 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.36 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.35 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.35 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.35 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.35 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.35 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.34 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.34 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.34 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.34 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.34 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.34 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.34 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pseudotropine SCHEMBL228982 | 1.00 | LMNA (0.94) | LMNACYP2C9CHRM3CHRM2CHRM1 | |
| Pseudotropine SCHEMBL64824 | 0.97 | LMNA (1.00) | LMNACYP2C9CHRM3CHRM2CHRM1 | |
| Pseudotropine SCHEMBL21563309 | 0.97 | LMNA (1.00) | LMNACYP2C9CHRM3CHRM2CHRM1 | |
| Pseudotropine SCHEMBL100196 | 0.97 | LMNA (1.00) | LMNACYP2C9CHRM3CHRM2CHRM1 | |
| Pseudotropine SCHEMBL31078606 | 0.97 | LMNA (1.00) | LMNACYP2C9CHRM3CHRM2CHRM1 | |
| Pseudotropine SCHEMBL2442824 | 0.97 | LMNA (1.00) | LMNACYP2C9CHRM3CHRM2CHRM1 | |
| Pseudotropine SCHEMBL745726 | 0.97 | LMNA (1.00) | LMNACYP2C9CHRM3CHRM2CHRM1 | |
| Pseudotropine SCHEMBL6944859 | 0.97 | LMNA (1.00) | LMNACYP2C9CHRM3CHRM2CHRM1 | |
| Pseudotropine SCHEMBL38978 | 0.97 | LMNA (1.00) | LMNACYP2C9CHRM3CHRM2CHRM1 | |
| Pseudotropine SCHEMBL7296801 | 0.94 | LMNA (0.94) | LMNACYP2C9CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1733761-A | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and the use thereof in the production of a medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-02-15 | — | — | CN | claimed |
| CN-1221549-C | Crystalline monohydrate, method for the production thereof and use thereof for producing pharmaceutical combinations | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-10-05 | — | — | CN | claimed |
| CN-1646108-A | Aerosol formulation for inhalation comprising a tiotropium salt | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-07-27 | — | — | CN | claimed |
| CN-1642952-A | Micronized crystalline tiotropium bromide | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-07-20 | — | — | CN | claimed |
| CN-1469877-A | Crystalline monohydrate, method for the production thereof and use thereof for producing pharmaceutical combinations | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-01-21 | — | — | CN | claimed |
| US-5759727-A | TONER IMAGE ON TRANSPARENT SUBSTRATE; MELT POLYMER BACKING | XEROX CORPORATION (US) | 1998-06-02 | — | — | US | claimed |
| CN-107995861-A | Inhalation solution of tiotropium for atomization | 格兰马克专业公司 | 2018-05-04 | — | — | CN | disclosed |
| EP-2477984-B1 | A METHOD FOR THE N-DEMETHYLATION OF N-METHYL HETEROCYCLES | UNIV MONASH (AU) | 2016-08-03 | — | — | EP | disclosed |
| US-9073934-B2 | Method for the N-demethylation of N-methyl heterocycles | MONASH UNIVERSITY (AU) | 2015-07-07 | — | — | US | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120226043-A1 | METHOD FOR THE N-DEMETHYLATION OF N-METHYL HETEROCYCLES | MONASH UNIVERSITY (AU) | 2012-09-06 | — | — | US | disclosed |
| EP-2477984-A1 | A METHOD FOR THE N-DEMETHYLATION OF N-METHYL HETEROCYCLES | Monash University (AU) | 2012-07-25 | — | — | EP | disclosed |
| CN-1469877-A | Crystalline monohydrate, method for the production thereof and use thereof for producing pharmaceutical combinations | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-01-21 | — | — | CN | disclosed |
| US-6676925-B1 | BINDING WITH 9-AZABICYCLO(3.3.1)NONANE DERIVATIVES DETECTIVELY LABELED FOR POSITRON OR SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY IMAGING | WAKE FOREST UNIVERSITY | 2004-01-13 | — | — | US | disclosed |
| EP-0888345-A4 | SIGMA-2 RECEPTORS AS BIOMARKERS OF TUMOR CELL PROLIFERATION | UNIV WAKE FOREST (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6113877-A | ADMINISTERING 8-AZABICYCLO(3.2.1)OCTANE OR 9-AZABICYCLO(3.3.1)NONANE DERIVATIVES; DETERMINING BREAST CANCER THERAPY | WAKE FOREST UNIVERSITY (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0888345-A1 | SIGMA-2 RECEPTORS AS BIOMARKERS OF TUMOR CELL PROLIFERATION | WAKE FOREST UNIVERSITY (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5759727-A | TONER IMAGE ON TRANSPARENT SUBSTRATE; MELT POLYMER BACKING | XEROX CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| WO-1997034892-A1 | SIGMA-2 RECEPTORS AS BIOMARKERS OF TUMOR CELL PROLIFERATION | WAKE FOREST UNIVERSITY (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226043-A1 | METHOD FOR THE N-DEMETHYLATION OF N-METHYL HETEROCYCLES | TET3, DNMT1, TET2 | CHRM3 583/4885CHRM2 1060/4885CHRM1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.